SWKH - NASDAQ
SWK Holdings Corporation
$15.90
+0.0000%SWK Holdings Corporation, a specialty finance company that focuses on the healthcare sector. It operates in two segments, Finance Receivables and Pharmaceutical Development. The company provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. It also offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. In addition, the company engages in the pharmaceutical development, formulation and manufacturing, and licensing business through the Peptelligence platform. Further, it intends to out-license its internal product pipeline to create novel formulations using its proprietary technology to develop treatments for patients and caregivers. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was founded in 1996 and is headquartered in Dallas, Texas.
At a Glance
Live SnapshotSWK Holdings Corporation Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Outstanding operational efficiency. The company generates substantial profit from core operations.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Effective Tax Rate
Higher tax burden may reflect limited tax optimization or operations in high-tax jurisdictions.
Profitability Insight
Interest or tax burden: Strong operational performance but thin net margins indicate high interest expenses or unfavorable tax position eating into profits.
SWK Holdings Corporation Income Statement
SWKH • NASDAQ
| SWK Holdings Corporation Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
40.8M | 45M | 37.8M | 41.5M | 56.2M | 36.7M | 30.7M | 26M | 37.5M | 22.4M | 23.5M | 17.4M | 6.4M | 637K | 0.0 | 0.0 | 45.3M | 65.2M | 60.8M | 54M | |
GROSS PROFIT | ||||||||||||||||||||
(1.9M) | (2.2M) | (3.4M) | (7M) | (7.3M) | (4.3M) | (1.2M) | (0.0) | (0.0) | (0.0) | (10K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (16.5M) | (20.7M) | (17.2M) | (12.9M) | |
38.8M | 42.8M | 34.3M | 34.5M | 48.8M | 32.4M | 29.6M | 26M | 37.5M | 22.4M | 23.5M | 17.4M | 6.4M | 637K | 0.0 | 0.0 | 28.7M | 44.5M | 43.6M | 41.1M | |
OPERATING INCOME | ||||||||||||||||||||
(14.8M) | (31.2M) | (19.7M) | (24.6M) | (17.8M) | (22.6M) | (14.6M) | (11.1M) | (4.1M) | (4.5M) | (14.2M) | (3.3M) | (1.7M) | (2.2M) | (1.5M) | (1.8M) | (35.8M) | (47.2M) | (50.1M) | (40.7M) | |
(14.8M) | (11.5M) | (11.2M) | (13M) | (13.6M) | (10.5M) | (7.4M) | (4.9M) | (4.1M) | (2.8M) | (3.4M) | (3.3M) | (1.7M) | (2.2M) | (1.5M) | (1.8M) | (17.9M) | (32.9M) | (37.2M) | (29.8M) | |
(1.6M) | (2.2M) | (0.0) | (0.0) | (0.0) | (0.0) | (1.2M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (12.8M) | (13.8M) | (12.7M) | (10.8M) | |
24M | 11.6M | 14.7M | 10M | 31M | 9.8M | 15M | 14.9M | 33.4M | 17.9M | 2.6M | 14.1M | 4.7M | -1.6M | -1.5M | -1.8M | -8.4M | -3.2M | -7.1M | -271K | |
PRE-TAX INCOME | ||||||||||||||||||||
(4.8M) | (4.7M) | (1.8M) | (340K) | (374K) | (455K) | (338K) | (160K) | (0.0) | (0.0) | (381K) | (589K) | (68K) | (158K) | (254K) | (275K) | (978K) | (369K) | (858K) | (207K) | |
33.6M | -4.7M | -1.8M | -340K | -374K | -455K | -338K | -160K | 0.0 | 15.8M | -381K | -579K | -19K | 158K | 0.0 | 0.0 | -971K | -342K | -771K | -35K | |
-1.5M | (17.5M) | (8.4M) | (11.6M) | (4.1M) | (12.1M) | (7.2M) | (6.2M) | (0.0) | (1.7M) | (10.8M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (5.1M) | (500K) | (288K) | (133K) | |
-3.9M | 6.8M | -37K | -477K | 2M | -6.1M | -3.9M | -673K | -9.4M | -7.5M | -3.7M | -824K | -209K | 158K | 453K | 1M | 43.3M | -411K | -739K | -1.9M | |
20.1M | 18.4M | 14.6M | 9.5M | 33M | 3.7M | 16.8M | 6.2M | 24M | 10.4M | -1.1M | 13.3M | 4.5M | -1.4M | -1.1M | -727K | 34.9M | -3.7M | -7.9M | -2.2M | |
NET INCOME | ||||||||||||||||||||
(22.6M) | (4.9M) | -1.3M | -4M | (7.1M) | -1.5M | -7M | (42K) | (15.8M) | -21.6M | (3.3M) | -10.3M | -9.8M | -24K | -26K | -20K | (3K) | (5K) | (167K) | (219K) | |
-2.5M | 13.5M | 15.9M | 13.5M | 25.9M | 5.2M | 23.8M | 6.2M | 3M | 28.9M | -7.4M | 20.8M | 12.9M | -1.4M | -1.1M | -707K | 34.9M | -3.7M | -8M | -2.4M |
SEC Filings
SWKH - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | April 06, 2026 | April 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 31, 2026 | March 31, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 20, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 13, 2026 | February 13, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 05, 2025 | December 04, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 04, 2025 | December 02, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 10, 2025 | October 09, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 09, 2025 | October 09, 2025 | 2025 |
Related Guides
Continue your SWKH research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.